Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Tango Therapeutics Inc (TNGX)

Tango Therapeutics Inc (TNGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Tango Therapeutics Appoints Robert Azelby to Board of Directors GlobeNewswire - Mon Jun 22, 3:05PM CDT

BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer...

TNGX : 31.47 (+4.41%)
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering GlobeNewswire - Tue Jun 9, 9:49PM CDT

BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of...

TNGX : 31.47 (+4.41%)
Biotech research by Gorodenkoff via Shutterstock
Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial Results Barchart - Tue Jun 9, 8:29AM CDT

Tango Therapeutics shares rallied on Monday after recording impressive results for its pancreatic cancer drug. Here’s how you should play TNGX stock at current levels.

IDYA : 36.74 (+1.24%)
JNJ : 254.66 (+3.99%)
INCY : 113.75 (+5.78%)
TNGX : 31.47 (+4.41%)
RHHBY : 51.7400 (-0.23%)
Tango Therapeutics Announces Proposed $500 Million Public Offering GlobeNewswire - Mon Jun 8, 3:01PM CDT

BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of...

TNGX : 31.47 (+4.41%)
Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer GlobeNewswire - Mon Jun 8, 5:59AM CDT

Initial data from ongoing Phase 1/2 trial in patients with second and third line PDAC treated with vopimetostat and daraxonrasib showed 6-month PFS rate of 90% (median PFS not yet reached) suggesting durability...

TNGX : 31.47 (+4.41%)
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Jun 5, 6:00AM CDT

BOSTON, June 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that, effective June 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted...

TNGX : 31.47 (+4.41%)
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights GlobeNewswire - Wed May 13, 3:07PM CDT

First clinical data from PRMT5/RAS(ON) combination trial to be pre sented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection...

TNGX : 31.47 (+4.41%)
Tango Therapeutics Pivotal Trial Launch Timing Matters More Than the Vopimetostat Monotherapy Data Barchart - Sun May 10, 4:00PM CDT

Barchart Research What to Expect from TNGX Earnings TNGX Generated May 8, 2026 Current Price $23.02 EPS Estimate $$-0.32 Consensus Rating Strong Buy Average Move 12.99% Tango Therapeutics Pivotal Trial...

TNGX : 31.47 (+4.41%)
Tango Therapeutics Pivotal Trial Launch Timing Matters More Than the Vopimetostat Monotherapy Data Barchart - Sat May 9, 4:01PM CDT

Barchart Research What to Expect from TNGX Earnings TNGX Generated May 8, 2026 Current Price $23.02 EPS Estimate $$-0.32 Consensus Rating Strong Buy Average Move 12.99% Tango Therapeutics Pivotal Trial...

TNGX : 31.47 (+4.41%)
Tango Therapeutics Pivotal Trial Launch Timing Matters More Than the Vopimetostat Monotherapy Data Barchart - Fri May 8, 4:12PM CDT

Barchart Research What to Expect from TNGX Earnings TNGX Generated May 8, 2026 Current Price $23.02 EPS Estimate $$-0.32 Consensus Rating Strong Buy Average Move 12.99% Tango Therapeutics Pivotal Trial...

TNGX : 31.47 (+4.41%)

Barchart Exclusives

SpaceX Stock Has Already Lost Most of Its IPO Gains. It’s Not Time to Buy Until Shares Fall Below $135. Barchart - 25 minutes ago
Here's to play SpaceX amid the selloff triggered in part by a debt funding plan. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.